Fezolinetant

Extended indication	Behandeling van matige tot ernstige menopauze gerelateerde vasomotorische symptomen
Therapeutic value	No estimate possible yet
Registration phase	Registration application pending

Product

Active substance	Fezolinetant
Domain	Metabolism and Endocrinology
Reason of inclusion	New medicine (specialité)
Main indication	Metabolic diseases
Extended indication	Behandeling van matige tot ernstige menopauze gerelateerde vasomotorische symptomen
Proprietary name	unknown
Manufacturer	Astellas
Portfolio holder	Astellas
Mechanism of action	Receptor antagonist
Route of administration	Oral
Therapeutical formulation	Tablet
Budgetting framework	Extramural (GVS)
Additional remarks	Neurokinine-3-receptor antagonist

Registration route	Centralised (EMA)
ATMP	No
Submission date	September 2022
Expected Registration	October 2023
Orphan drug	No
Registration phase	Registration application pending

Current treatment options	De standaard geneesmiddelbehandeling voor vasomotorische symptomen in de menopauze is hormoontherapie met een combinatie van oestrogeen en progesteron, of oestrogeen alleen.
Therapeutic value	No estimate possible yet
Frequency of administration	1 times a day

There is currently nothing known about the expected patient volume.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

Indication extension	No
References	adisinsght

There is currently no futher information available.